Press releases

Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences. On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...

Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...

The EXALT Model D Duodenoscope is the first and only FDA cleared single-use duodenoscope on the market.

Boston Scientific Corporation is scheduled to participate in two investor conferences in December 2019.

Boston Scientific completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.

Boston Scientific announced a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

Boston Scientific will participate in four conferences in November 2019. Learn how to join the webcasts or watch the replays for each event.

"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2019.

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

Boston Scientific CEO Mike Mahoney will participate in a conference in September 2019. Learn how to join the webcast or watch the replay.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

Physicians will have continued access to the Eluvia™ Drug-Eluting Vascular Stent (DES) System to treat their patients with peripheral artery disease (PAD).

Boston Scientific will participate in an upcoming investor conference in August 2019. A live webcast and replay will be available.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2019. Learn how to tune in.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.

Boston Scientific shares the FDA’s dedication to providing the best care possible for the 8.5 million patients in the U.S. with peripheral artery disease (PAD).

Data on the Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System were not included in the meta-analyses that were catalysts for the panel meeting.

Vertiflex acquisition adds the only FDA-approved, commercially available, minimally invasive interspinous spacer to Boston Scientific’s chronic pain portfolio.

WATCHMAN device findings could expand number of non-valvular atrial fibrillation (AFib) patients who can receive alternative treatment to lifelong use of blood thinners.

Boston Scientific (BSX) will participate in an upcoming investor conference in May 2019. A live webcast and replay will be available.

New clinical trial data further support use of Boston Scientific’s EMBLEM S-ICD System as first-line therapy for majority of ICD patients.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

Boston Scientific will participate in the upcoming healthcare conference in May 2019. A live webcast and replay will be available.

New stent system now available for treating patients with deep venous blockages.

Results includes data about Boston Scientific S-ICD, POLARx cryoablation catheter, WATCHMAN device and LUX-Dx insertable cardiac monitor.

Boston Scientific will participate in the upcoming investor healthcare conference in May 2019. A live webcast and replay will be available.

"With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook,” said CEO Mike Mahoney. Read the April 2019 release.

Transcatheter aortic valve replacement technology for patients with severe aortic stenosis designed to minimize paravalvular leakage, offer controlled delivery and repositionability post deployment.

The inaccessibility of these products will severely limit treatment options for the 50% of women in the U.S. who will suffer from POP during their lives.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2019.

New data showcases safety & efficacy of recently acquired RF balloon-based, single-shot ablation technology when treating patients with AFib.

Company begins limited market release in Europe for next generation WATCHMAN device, intended to reduce the risk of stroke in people with non-valvular AFib.

Key data to be featured at European Heart Rhythm Association (EHRA) Congress include outcomes from the LUMINIZE RF balloon catheter for the treatment of AFib.

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions.

Boston Scientific will participate in the upcoming healthcare conference in February 2019. A live webcast and replay will be available.

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the SVB Leerink healthcare conference in February 2019. A live webcast and replay will be available.

Patient safety is always our highest priority at Boston Scientific.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.